Skip to main content
Top
Published in: Breast Cancer Research 5/2005

Open Access 01-10-2005 | Research article

Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan

Authors: Nidal M Almasri, Mohammad Al Hamad

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Introduction

Although breast carcinoma (BC) is the most common malignancy affecting Jordanian females and the affected population in Jordan is younger than that in the West, no information is available on its biological characteristics. Our aims in this study are to evaluate the expression of estrogen receptor (ER) and progesterone receptor (PR) and Her-2/neu overexpression in BC in Jordan, and to compare the expression of these with other prognostic parameters for BC such as histological type, histological grade, tumor size, patients' age, and number of lymph node metastases.

Method

This is a retrospective study conducted in the Department of Pathology at Jordan University of Science and Technology. A confirmed 91 cases of BC diagnosed in the period 1995 to 1998 were reviewed and graded. We used immunohistochemistry to evaluate the expression of ER, PR, and Her-2. Immunohistochemical findings were correlated with age, tumor size, grade and axillary lymph node status.

Results

Her-2 was overexpressed in 24% of the cases. The mean age of Her-2 positive cases was 42 years as opposed to 53 years among Her-2 negative cases (p = 0.0001). Her-2 expression was inversely related to ER and PR expression. Her-2 positive tumors tended to be larger than Her-2 negative tumors with 35% overexpression among T3 tumors as opposed to 22% among T2 tumors (p = 0.13). Her-2 positive cases tended to have higher rates of axillary metastases, but this did not reach statistical significance. ER and PR positive cases were seen in older patients with smaller tumor sizes.

Conclusion

Her-2 overexpression was seen in 24% of BC affecting Jordanian females. Her-2 overexpression was associated with young age at presentation, larger tumor size, and was inversely related to ER and PR expression. One-fifth of the carcinomas were Her-2 positive and ER negative. This group appears to represent an aggressive form of BC presenting at a young age with large primary tumors and a high rate of four or more axillary lymph node metastases.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jordan Cancer Registry, Ministry of Health: Cancer Incidence in Jordan 1997 Report. Amman. 2000 Jordan Cancer Registry, Ministry of Health: Cancer Incidence in Jordan 1997 Report. Amman. 2000
2.
go back to reference Dajani YF, Al-Jitawi SA: A study of 405 breast tumors in Jordanians using the revised WHO classification. Trop Geogr Med. 1987, 39: 182-186.PubMed Dajani YF, Al-Jitawi SA: A study of 405 breast tumors in Jordanians using the revised WHO classification. Trop Geogr Med. 1987, 39: 182-186.PubMed
3.
go back to reference Amr SS: Breast diseases in Jordanian females: a study of 1000 cases. Eur J Surg Oncol. 1985, 11: 257-262.PubMed Amr SS: Breast diseases in Jordanian females: a study of 1000 cases. Eur J Surg Oncol. 1985, 11: 257-262.PubMed
4.
go back to reference Kamal MF: Cancer patterns in Jordan 1975–1979. Annals Chirurgiae Gunaecologiae. 1987, 76: 191-196. Kamal MF: Cancer patterns in Jordan 1975–1979. Annals Chirurgiae Gunaecologiae. 1987, 76: 191-196.
5.
go back to reference Abalkhail AA, Zahawi HM, Almasri NM, Hameed OK: The role of young population structure in determining age distribution of breast cancer in Jordan. J Bahrain Med Society. 2003, 15: 28-33. Abalkhail AA, Zahawi HM, Almasri NM, Hameed OK: The role of young population structure in determining age distribution of breast cancer in Jordan. J Bahrain Med Society. 2003, 15: 28-33.
6.
go back to reference Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.CrossRef
7.
go back to reference Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed
8.
go back to reference Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182.CrossRefPubMed
9.
go back to reference Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712.CrossRefPubMed
10.
go back to reference Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998, 34: 791-808. 10.1016/S0959-8049(97)10157-5.CrossRefPubMed Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998, 34: 791-808. 10.1016/S0959-8049(97)10157-5.CrossRefPubMed
11.
go back to reference Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996, 13: 63-72.PubMed Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996, 13: 63-72.PubMed
12.
go back to reference Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1994, 29: 3-9. 10.1007/BF00666177.CrossRefPubMed Rajkumar T, Gullick WJ: The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat. 1994, 29: 3-9. 10.1007/BF00666177.CrossRefPubMed
13.
14.
go back to reference Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003, 8: 307-325. 10.1634/theoncologist.8-4-307.CrossRefPubMed Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003, 8: 307-325. 10.1634/theoncologist.8-4-307.CrossRefPubMed
15.
go back to reference Hanna W, Kahn HJ, Trudeau M: Evaluation of Her-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol. 1999, 12: 827-834.PubMed Hanna W, Kahn HJ, Trudeau M: Evaluation of Her-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol. 1999, 12: 827-834.PubMed
16.
go back to reference Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995, 31A: 2185-2190. 10.1016/0959-8049(95)00344-4.CrossRefPubMed Stal O, Sullivan S, Wingren S, Skoog L, Rutqvist LE, Carstensen JM, Nordenskjold B: c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995, 31A: 2185-2190. 10.1016/0959-8049(95)00344-4.CrossRefPubMed
17.
go back to reference Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994, 330: 1260-1266. 10.1056/NEJM199405053301802.CrossRefPubMed Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994, 330: 1260-1266. 10.1056/NEJM199405053301802.CrossRefPubMed
18.
go back to reference Huston JS, George AJ: Engineered antibodies take center stage. Hum Antibodies. 2001, 10: 127-142.PubMed Huston JS, George AJ: Engineered antibodies take center stage. Hum Antibodies. 2001, 10: 127-142.PubMed
19.
go back to reference Hortobagyi GN: Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001, 28: 43-47. 10.1053/sonc.2001.29710.CrossRefPubMed Hortobagyi GN: Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol. 2001, 28: 43-47. 10.1053/sonc.2001.29710.CrossRefPubMed
20.
go back to reference McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002, 62: 209-243.CrossRefPubMed McKeage K, Perry CM: Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002, 62: 209-243.CrossRefPubMed
21.
go back to reference Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9.CrossRefPubMed Shawver LK, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9.CrossRefPubMed
22.
go back to reference Ligibel JA, Winer EP: Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002, 29: 38-43. 10.1053/sonc.2002.34054.CrossRefPubMed Ligibel JA, Winer EP: Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol. 2002, 29: 38-43. 10.1053/sonc.2002.34054.CrossRefPubMed
23.
go back to reference Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
24.
go back to reference Tavassoli FA, Devilee P, Eds: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2004, Lyon: IARC Press Tavassoli FA, Devilee P, Eds: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 2004, Lyon: IARC Press
25.
go back to reference Elston CW, Ellis JO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a long study with long-term follow-up. Histopathology. 1991, 19: 403-410.CrossRefPubMed Elston CW, Ellis JO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a long study with long-term follow-up. Histopathology. 1991, 19: 403-410.CrossRefPubMed
26.
go back to reference Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000, 18: 3651-3664.CrossRefPubMed Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ: Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000, 18: 3651-3664.CrossRefPubMed
27.
go back to reference Varshney D, Zhou YY, Geller SA, Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004, 121: 70-77. 10.1309/FUQH-92B0-3902-5LHG.CrossRefPubMed Varshney D, Zhou YY, Geller SA, Alsabeh R: Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004, 121: 70-77. 10.1309/FUQH-92B0-3902-5LHG.CrossRefPubMed
28.
go back to reference Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG: A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer. 2003, 98: 1587-1595. 10.1002/cncr.11703.CrossRefPubMed Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffty BG: A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer. 2003, 98: 1587-1595. 10.1002/cncr.11703.CrossRefPubMed
29.
go back to reference Yang J, Xing T, Yao X, Hu R: Relationship of C-erbB-2 oncogene overexpression to estrogen progesterone receptors in breast cancer and its prognostic significance. Hua Xi Yi Ke Da Xue Xue Bao. 1997, 28: 214-217.PubMed Yang J, Xing T, Yao X, Hu R: Relationship of C-erbB-2 oncogene overexpression to estrogen progesterone receptors in breast cancer and its prognostic significance. Hua Xi Yi Ke Da Xue Xue Bao. 1997, 28: 214-217.PubMed
30.
go back to reference Abadjian G, Antoun R: Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban. 1996, 44: 10-15.PubMed Abadjian G, Antoun R: Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers. J Med Liban. 1996, 44: 10-15.PubMed
31.
go back to reference el-A Helal T, Khalifa A, Kamel AS: Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res. 2000, 20: 2145-2150.PubMed el-A Helal T, Khalifa A, Kamel AS: Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res. 2000, 20: 2145-2150.PubMed
32.
go back to reference Hoff ER, Tubbs RR, Myles JL, Procop GW: HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002, 117: 916-921. 10.1309/4NTU-N6K4-F8JF-EWRX.CrossRefPubMed Hoff ER, Tubbs RR, Myles JL, Procop GW: HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol. 2002, 117: 916-921. 10.1309/4NTU-N6K4-F8JF-EWRX.CrossRefPubMed
33.
go back to reference Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004, 6: R149-156. 10.1186/bcr767.CrossRefPubMedPubMedCentral Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004, 6: R149-156. 10.1186/bcr767.CrossRefPubMedPubMedCentral
34.
go back to reference Rosenthal SI, Depowski PL, Sheehan CE, Ross JS: Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol. 2002, 10: 40-46. 10.1097/00022744-200203000-00007.CrossRefPubMed Rosenthal SI, Depowski PL, Sheehan CE, Ross JS: Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol. 2002, 10: 40-46. 10.1097/00022744-200203000-00007.CrossRefPubMed
35.
go back to reference Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 1991, 68: 331-334.CrossRefPubMed Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM: C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer. 1991, 68: 331-334.CrossRefPubMed
36.
go back to reference Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, et al: Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer. 2003, 98: 2547-2553. 10.1002/cncr.11828.CrossRefPubMed Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, et al: Do we need HER-2/neu testing for all patients with primary breast carcinoma?. Cancer. 2003, 98: 2547-2553. 10.1002/cncr.11828.CrossRefPubMed
37.
go back to reference Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Bio. 2002, 34: 1318-1330. 10.1016/S1357-2725(02)00052-3.CrossRef Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC: Age-associated biomarker profiles of human breast cancer. Int J Biochem Cell Bio. 2002, 34: 1318-1330. 10.1016/S1357-2725(02)00052-3.CrossRef
38.
go back to reference Berger U, Wilson P, McClelland RA, Davidson J, Coombes RC: Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol. 1987, 18: 1263-1267.CrossRefPubMed Berger U, Wilson P, McClelland RA, Davidson J, Coombes RC: Correlation of immunocytochemically demonstrated estrogen receptor distribution and histopathologic features in primary breast cancer. Hum Pathol. 1987, 18: 1263-1267.CrossRefPubMed
39.
go back to reference Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998, 90: 1361-1370. 10.1093/jnci/90.18.1361.CrossRefPubMed Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N, et al: erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998, 90: 1361-1370. 10.1093/jnci/90.18.1361.CrossRefPubMed
40.
go back to reference Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer. 1994, 74: 2956-2963.CrossRefPubMed Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer. 1994, 74: 2956-2963.CrossRefPubMed
41.
go back to reference Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg. 1993, 218: 13-21.CrossRefPubMedPubMedCentral Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tuchler H: Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg. 1993, 218: 13-21.CrossRefPubMedPubMedCentral
42.
go back to reference Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A: Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences. Cancer. 1989, 64: 196-202.CrossRefPubMed Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A: Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences. Cancer. 1989, 64: 196-202.CrossRefPubMed
43.
go back to reference Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, et al: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000, 37: 536-545. 10.1046/j.1365-2559.2000.01006.x.CrossRefPubMed Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, et al: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology. 2000, 37: 536-545. 10.1046/j.1365-2559.2000.01006.x.CrossRefPubMed
44.
go back to reference Ferno M, Andersson C, Fallenius G, Idvall I: Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol. 1996, 35: 17-22.CrossRefPubMed Ferno M, Andersson C, Fallenius G, Idvall I: Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. The South Sweden Breast Cancer Group. Acta Oncol. 1996, 35: 17-22.CrossRefPubMed
45.
go back to reference Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR: Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol. 1998, 110: 758-764.CrossRefPubMed Layfield LJ, Saria E, Mooney EE, Liu K, Dodge RR: Tissue heterogeneity of immunohistochemically detected estrogen receptor. Implications for image analysis quantification. Am J Clin Pathol. 1998, 110: 758-764.CrossRefPubMed
46.
go back to reference Esteban JM, Ahn C, Mehta P, Battifora H: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol. 1994, 102: 158-162.CrossRefPubMed Esteban JM, Ahn C, Mehta P, Battifora H: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol. 1994, 102: 158-162.CrossRefPubMed
47.
go back to reference Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ: Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer. 1986, 58: 1076-1081.CrossRefPubMed Mohammed RH, Lakatua DJ, Haus E, Yasmineh WJ: Estrogen and progesterone receptors in human breast cancer. Correlation with histologic subtype and degree of differentiation. Cancer. 1986, 58: 1076-1081.CrossRefPubMed
48.
go back to reference Ashba J, Traish AM: Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients. Cancer Detect Prev. 1999, 23: 238-244. 10.1046/j.1525-1500.1999.99019.x.CrossRefPubMed Ashba J, Traish AM: Estrogen and progesterone receptor concentrations and prevalence of tumor hormonal phenotypes in older breast cancer patients. Cancer Detect Prev. 1999, 23: 238-244. 10.1046/j.1525-1500.1999.99019.x.CrossRefPubMed
49.
go back to reference Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001, 19: 18-27.CrossRefPubMed Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001, 19: 18-27.CrossRefPubMed
50.
go back to reference Chariyalertsak S, Chariyalertsak S, Cheirsilpa A, Sugano K, Ohkura H: Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer. J Med Assoc Thai. 1996, 79: 715-721.PubMed Chariyalertsak S, Chariyalertsak S, Cheirsilpa A, Sugano K, Ohkura H: Immunohistochemical detection of c-erbB-2 oncoprotein in patients with breast cancer. J Med Assoc Thai. 1996, 79: 715-721.PubMed
51.
go back to reference May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer. 1990, 62: 430-435.CrossRefPubMedPubMedCentral May E, Mouriesse H, May-Levin F, Qian JF, May P, Delarue JC: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer. 1990, 62: 430-435.CrossRefPubMedPubMedCentral
Metadata
Title
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan
Authors
Nidal M Almasri
Mohammad Al Hamad
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1200

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine